Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28088333 | 0.86 | KMO (0.48) | KMOGRIN2BACLYAKR1C2AKR1C1 | |
| SCHEMBL22815559 | 0.84 | KMO (0.50) | KMOGRIN2BACLYESR2AKR1C2 | |
| SCHEMBL22815715 | 0.84 | KMO (0.47) | KMOGRIN2BAKR1C2AKR1C1SLC1A5 | |
| SCHEMBL2095758 | 0.84 | KMO (0.47) | KMOGRIN2BACLYAKR1C2AKR1C1 | |
| SCHEMBL14741867 | 0.83 | KMO (0.51) | KMOGRIN2BSLC1A5KIF11 | |
| SCHEMBL2094887 | 0.81 | GRIN2B (0.46) | KMOGRIN2BAKR1C2AKR1C1 | |
| SCHEMBL2094886 | 0.81 | KMO (0.45) | KMOGRIN2BACLYAKR1C2AKR1C1 | |
| SCHEMBL18666773 | 0.80 | KMO (0.44) | KMOGRIN2BAKR1C2AKR1C1SLC1A5 | |
| SCHEMBL7396451 | 0.79 | MAPT (0.47) | ACLYKIF11LMNAMAPT | |
| SCHEMBL27699671 | 0.79 | ACLY (0.41) | ACLYKIF11LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KMO 248/4885GRIN2B 1562/4885ACLY 427/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KMO 255/4885GRIN2B 1717/4885ACLY 361/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | KMO 248/4885GRIN2B 1562/4885ACLY 427/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KMO 248/4885GRIN2B 1562/4885ACLY 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.